Novartis to prioritise US market, unfazed by drug pricing pu

Novartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.

Related Keywords

China , Germany , Zurich , Züsz , Switzerland , Japan , United States , Swiss , Joe Biden , Health Care , Swiss Exchange , Novartis , Inflation Reduction Act , Novartis News , Partd Drugs , Vas Narasimhan , Cosentyx , Entresto , Zolgensma , Kisqali , Kesimpta , Leqvio , Pluvicto , Scemblix , Sandoz ,